Embed Size (px)
DESCRIPTION
LAFERGS - Pharmaceutical Laboratory of Rio Grande do Sul
Citation preview
DOING BUSINESS IN RIO GRANDE DO SUL – BRAZIL
London, 8th May 2012
Pharmaceutical Industry
Challenges and Opportunities on the Public Sector
Paulo Mayorga
LAFERGS
Operários – Tarsila do Amaral
LAFERGS
Pharmaceutical Laboratory of Rio Grande do Sul
Public Laboratory
Industrial area of FEPPS
(Public Institution related to Research and Production in Health)
Able to produce solid, liquids and semi-solid medicines
Near future: Diagnostic products
FEPPS Organization Chart
1- NUPLAM/RN
2- LAFEPE/PE
3- HEMOBRÁS/PE
4- LIFAL/AL
5- BAHIAFARMA/BA
6- IQUEGO/GO
7- FUNED/MG
8- FAP/RJ
9- BIO-MANGUINHOS/RJ
10- FAR-MANGUINHOS/RJ
11- LFM/RJ
12- IVB/RJ
13- LQFEX/RJ
14- LQFA/RJ
15- BUTANTAN/SP
16- FURP/SP
17- TECPAR/PR
18 – LAFERGS/RS
Market regulation and Priority Programmes
(E.g. PA, AIDS, neglected diseases)
PUBLIC PHARMACEUTICAL LABS IN BRAZIL
18
17
15,16
8,9,10,11,12,13,14
7
6
2, 3
4
5
1
Our system in 2011
145 million assisted users
2 million professionals
3.2 billion ambulatory procedures
495 million medical consultations
23 thousand transplant procedures
11 million hospital admissions
425 million laboratory tests
216 thousand establishments
public medicines distribution
THE BRAZILIAN UNIVERSAL HEALTH CARE SYSTEM
General informations
PRESSURE IN HEALTH SYSTEM
Population aging and the epidemiological profile change
IBGE
Other diseases
Cardiovascular
External causes
Neoplasia
Infectious and
parasitic diseases
Proportional mortality in Brazil: 1930-2010
(PESS/NEPP/UNICAMP)
47,5 54,3
66,4 77,1
87,3 96,7
112
125,1
138,3
0
20
40
60
80
100
120
140
160
2002 2003 2004 2005 2006 2007 2008 2009 2010
Billion R$
INVESTMENT IN PUBLIC HEALTH SERVICES
2010
£ 43 billion
4% of GDP (Gross Domestic Product)
MS/FNS
Expenses in public health services (R$), 2002 - 2010
IMS Health, Market Prognosis (2009)
Contributions to global market growth (2009 – 2013)
PHARMACEUTICAL MARKET PROGNOSIS
“Pharmerging” markets contribution
DECIIS/SCTIE/MS
Expenses in Medicines by the Brazilian Government (R$), 2003 - 2011
PHARMACEUTICAL DEMANDS
Evolution of the public medicines market
2,81
4,02 4,40
5,10
6,37 7,01
8,96
10,79 11,37
0
2
4
6
8
10
12
2003 2004 2005 2006 2007 2008 2009 2010 2011
Billi
on
R$
£ 3,5 billion
U$ 6,3 billion)
DECIIS/SCTIE/MS
Purchases 2011
PHARMACEUTICAL DEMANDS
Public purchases of medicines
PHARMACEUTICAL DEMANDS
Specialized medicines – The highest cost group
GIS/ENSP/FIOCRUZ (2011)
1,47 1,80 1,86 2,31 2,43
7,18
9,00 9,00
11,66 11,85
- 5,70 - 7,21 - 7,14
- 9,35 - 9,42
- 15,00
- 10,00
- 5,00
0,00
5,00
10,00
15,00
2007 2008 2009 2010 2011 2012
Billi
on
US
$
Foreign Trade of Health Sector (2007 – 2011)
EXPORT IMPORT FOREIGN TRADE BALANCE
CURRENT ECONOMIC SCENARIO
Foreign trade deficit of the health sector
£ 5,3 billion
3 4
5 6
Production of equipment
and materials for use
in health
Reagents and devices
for Diagnostics by using
biotechnology
Production of medicines
and chemical synthesis
of drugs
Biotechnological
products for health
R&D and Inovation Challenges
1 Local blood production
(8 - 9 factors, albumine
and globulines) 2 Vaccine development
to National Program
of immunization 1
2
3
6
5
4
HEALTH SECTOR CHALLENGES
MDIC/MF/ABDI
GOALS:
Stimulate the local production of high cost or high social impact products
Stimulate the development of new medicines
Expand the population access to the medicines
IMPROVE THE CURRENT MEDICINES PRODUCTION
PHARMACEUTICAL CHALLENGE
THE OPORTUNITIES
Development strategies
Strengthening industrial policy
Consolidation of public pharmaceutical labs
Use the purchase power of the government
Industrial Policy Purchase Power Public Production Development Strategies
DECIIS/SCTIE/MS
Strategic actions in order to build competitiveness
Available resources for all stages of the innovation cycle
Shared goals with the private sector
Health industrial
complex
Nanotechnology
Information and
communication
technologies
Biotechnology
Nuclear energy
Defense industrial
complex
THE OPORTUNITIES
Industrial Policy and Strategic Sectors
Industrial Policy Purchase Power Public Production Development Strategies
MDIC/MF/ABDI
2000 - 2011 2012 2012 - 2015
R$ 512 million
(£ 160 million)
R$ 250 million
(£ 78,1 million)
R$ 1 billion
(£ 312,5 million)
0
50
100
150
200
250
300
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
THE OPORTUNITIES
Investment in Public Labs (2000 – 2015)
Industrial Policy Purchase Power Public Production Development Strategies
Bill
ion
R$
DECIIS/SCTIE/MS
Partnerships for production
(With technology transfer)
Technological orders
(Linked to specific demands)
Legal support
(Resolutions of the Ministry of Health)
THE OPORTUNITIES
Optimization of the public purchases
Industrial Policy Purchase Power Public Production Development Strategies
PARTNERSHIPS OPORTUNITIES FOR PRODUCTION
Industrial Policy Purchase Power Public Production Development Strategies
Government
Private
Lab
Public
Lab
Executive project
Local development
5-years of partnership
Government ensures purchase
Technology transfer to the public lab
After technology transfer: provision of the active ingredient
HOW DOES IT WORK?
DECIIS/SCTIE/MS
IN CONCLUSION
Why is LAFERGS here?
WE ARE LOOKING FOR:
Potential partners
Specific products of interest:
Neglected diseases
Specialized medicines
Oncology
Transdermal systems
Aerosols
MAB
Peptides
Diagnostic products
